Stock Analiz

Anika Therapeutics, Inc. ANIK

Medical/Dental Instruments · data as of November 13, 2026

$13.40Market cap $179M
Open the interactive analysis →

Anika Therapeutics, Inc. (ANIK) is a healthcare company listed in the US with a market value of about $179M. In the twelve months to September 30, 2026 it had revenue of $123M and net income of -$2M, a net margin of -1.4%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 78.2, 5-year revenue growth of -3% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 76% below the current price.

About Anika Therapeutics

Anika Therapeutics is listed in the US and classified in medical/dental instruments. Revenue went from $106M in 2014 to $113M in 2025, growth of about 0.6% a year. It was profitable in 5 of the last 10 years in our data. Its share count fell by 3% over three years (buybacks). It spends 23% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health3/5
Shareholder returns1/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF78.2
P/S1.5
P/B1.3
EV/EBITDA52.4
PEG—
Dividend yield0.00%
FCF yield1.3%
Shareholder yield5.3%
Intrinsic value vs. price−76%

Growth and quality

Revenue growth (1 yr)-5.9%
Revenue growth (5 yrs, per year)-2.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-27.1%
ROIC (5-yr avg.)-1.2%
Profitable years (of last 10)5
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$123M$113M$120M$121M$114M$148M$130M$115M$106M$113M$103M
Net income-$2M-$11M-$56M-$83M-$15M$4M-$24M$27M$19M$32M$33M
Free cash flow$2M$4M-$2M-$7M-$3M$3M$11M$34M$30M$32M$10M
EPS (diluted)$-0.13$-0.76$-3.83$-5.64$-1.02$0.28$-1.69$1.89$1.27$2.11$2.15
Net margin-1.4%-9.6%-47.0%-68.4%-13.1%2.8%-18.4%23.7%17.7%28.1%31.5%
ROIC—-5.1%-2.2%0.3%0.6%0.7%-8.1%8.3%6.7%11.9%14.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Anika Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 76% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Anika Therapeutics pay a dividend?

Not currently.

Is Anika Therapeutics a good stock to buy?

We do not give buy or sell advice. Anika Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.